Western Europe Cancer Hormone Therapy Market (2021–2031)
The Western Europe cancer hormone therapy market size is expected to reach US$ 12,585.2 million by 2031 from US$ 6,096.8 million in 2024. The market is estimated to record a CAGR of 10.9% from 2025 to 2031.
Report Coverage
- Drug Class: GnRH Analogs, GnRH Antagonists, Androgen Receptor Antagonists, Aromatase Inhibitors, Selective Estrogen Receptor Modulators, Estrogen Receptor Antagonists, Thyroid Hormone Therapy, Other Drug Classes
- Cancer Type: Breast Cancer, Prostate Cancer, Endometrial Cancer, Ovarian Cancer, Thyroid Cancer, Other Cancer Types
- Route of Administration: Oral, Injectable, Implantable
- Sales Channel: Hospitals, Cancer Treatment Centers, Specialty Clinics, Retail Pharmacies
US$ 6,096.8 Mn
Market size in 2024
US$ 12,585.2 Mn
Market Size by 2031
10.9%
CAGR, 2025 - 2031
2025-2031
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Western Europe Cancer Hormone Therapy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Western Europe Cancer Hormone Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Western Europe Cancer Hormone Therapy Market Regional Analysis
6.2 Western Europe Cancer Hormone Therapy Market Revenue 2021-2031 (US$ Million)
6.3 Western Europe Cancer Hormone Therapy Market Forecast Analysis
7. Western Europe Cancer Hormone Therapy Market Analysis – by Drug Class
7.1 GnRH Analogs
- 7.1.1 Overview
- 7.1.2 GnRH Analogs: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 GnRH Antagonists
- 7.2.1 Overview
- 7.2.2 GnRH Antagonists: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Androgen Receptor Antagonists
- 7.3.1 Overview
- 7.3.2 Androgen Receptor Antagonists: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Aromatase Inhibitors
- 7.4.1 Overview
- 7.4.2 Aromatase Inhibitors: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Selective Estrogen Receptor Modulators
- 7.5.1 Overview
- 7.5.2 Selective Estrogen Receptor Modulators: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Estrogen Receptor Antagonists
- 7.6.1 Overview
- 7.6.2 Estrogen Receptor Antagonists: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Thyroid Hormone Therapy
- 7.7.1 Overview
- 7.7.2 Thyroid Hormone Therapy: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Other Drug Classes
- 7.8.1 Overview
- 7.8.2 Other Drug Classes: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Western Europe Cancer Hormone Therapy Market Analysis – by Cancer Type
8.1 Breast Cancer
- 8.1.1 Overview
- 8.1.2 Breast Cancer: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Prostate Cancer
- 8.2.1 Overview
- 8.2.2 Prostate Cancer: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Endometrial Cancer
- 8.3.1 Overview
- 8.3.2 Endometrial Cancer: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Ovarian Cancer
- 8.4.1 Overview
- 8.4.2 Ovarian Cancer: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Thyroid Cancer
- 8.5.1 Overview
- 8.5.2 Thyroid Cancer: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Other Cancer Types
- 8.6.1 Overview
- 8.6.2 Other Cancer Types: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Western Europe Cancer Hormone Therapy Market Analysis – by Route of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Injectable
- 9.2.1 Overview
- 9.2.2 Injectable: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Implantable
- 9.3.1 Overview
- 9.3.2 Implantable: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Western Europe Cancer Hormone Therapy Market Analysis – by Sales Channel
10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Hospitals: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Cancer Treatment Centers
- 10.2.1 Overview
- 10.2.2 Cancer Treatment Centers: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Specialty Clinics
- 10.3.1 Overview
- 10.3.2 Specialty Clinics: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.4 Retail Pharmacies
- 10.4.1 Overview
- 10.4.2 Retail Pharmacies: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
11. Western Europe Cancer Hormone Therapy Market – Western Europe Analysis
11.1 Overview
11.2 Western Europe- 11.2.1 Western Europe Cancer Hormone Therapy Market Breakdown, by Key Country, 2025 and 2031 (%)
- 11.2.1.1 Western Europe Cancer Hormone Therapy Market – Revenue and Forecast Analysis – by Country
- 11.2.1.1 Belgium: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.1.1 Belgium: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.1.2 Belgium: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.1.3 Belgium: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.1.4 Belgium: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.2 Netherlands: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.2.1 Netherlands: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.2.2 Netherlands: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.2.3 Netherlands: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.2.4 Netherlands: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.3 Luxembourg: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.3.1 Luxembourg: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.3.2 Luxembourg: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.3.3 Luxembourg: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.3.4 Luxembourg: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.4 Germany: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.4.1 Germany: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.4.2 Germany: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.4.3 Germany: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.4.4 Germany: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.5 France: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.5.1 France: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.5.2 France: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.5.3 France: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.5.4 France: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.6 Italy: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.6.1 Italy: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.6.2 Italy: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.6.3 Italy: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.6.4 Italy: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.7 Spain: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.7.1 Spain: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.7.2 Spain: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.7.3 Spain: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.7.4 Spain: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.8 Switzerland: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.8.1 Switzerland: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.8.2 Switzerland: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.8.3 Switzerland: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.8.4 Switzerland: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.9 Sweden: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.9.1 Sweden: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.9.2 Sweden: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.9.3 Sweden: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.9.4 Sweden: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.10 Austria: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.10.1 Austria: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.10.2 Austria: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.10.3 Austria: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.10.4 Austria: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.11 United Kingdom: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.11.1 United Kingdom: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.11.2 United Kingdom: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.11.3 United Kingdom: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.11.4 United Kingdom: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.12 Denmark: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.12.1 Denmark: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.12.2 Denmark: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.12.3 Denmark: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.12.4 Denmark: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.13 Portugal: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.13.1 Portugal: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.13.2 Portugal: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.13.3 Portugal: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.13.4 Portugal: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.14 Norway: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.14.1 Norway: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.14.2 Norway: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.14.3 Norway: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.14.4 Norway: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.15 Finland: Western Europe Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.15.1 Finland: Western Europe Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.15.2 Finland: Western Europe Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.15.3 Finland: Western Europe Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.15.4 Finland: Western Europe Cancer Hormone Therapy Market Breakdown, by Sales Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Pfizer Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 AbbVie
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Johnson & Johnson
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Novartis AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 AstraZeneca
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Sanofi
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Eli Lilly and Co
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 F. Hoffmann-La Roche Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Astellas Pharma Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Ipsen Pharma
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Access the Full Western Europe Cancer Hormone Therapy Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.